MALCOVA
MALCOVA is a pre-revenue medical device startup developing a patented Narrow-Beam CT scanner, proprietary Digital and Physical Twin models, and an AI-based Diagnostic Agent for early breast cancer detection in dense breast tissue and stroke imaging. It is Newark, California-based and founder-led as of 2025.
- Company typePrivate
- Founded2021
- HeadquartersNewark, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What MALCOVA does
MALCOVA (Malcova, Inc.) is a Newark, California-based medical device startup developing a proprietary hardware-and-software imaging platform for early disease detection, with an initial clinical focus on breast cancer in women with dense breast tissue and acute stroke. The platform is built around four integrated innovations: a patented Narrow-Beam CT scanner that delivers scatter-free, gantry-free 3D imaging at substantially lower radiation doses than conventional CT; high-fidelity Digital Twins that simulate breast tissue morphology to produce bias-controllable AI training data; patient-derived Physical Twins (scan-ready phantoms) that enable repeatable imaging without radiation exposure; and an AI-based Diagnostic Agent intended to assist radiologists. Technical credibility is anchored in peer-reviewed publications in Medical Physics and Physics in Medicine & Biology, including work characterizing scatter contamination in breast CT. The company applies a vertical segmentation approach targeting two primary segments, women with dense breast tissue and the radiologists/healthcare providers serving them, with stroke detection referenced as an adjacent use case.
MALCOVA is pre-revenue and does not publicly disclose pricing. Its go-to-market is enterprise field-sales oriented, relying on direct outreach to hospitals, imaging centers, and healthcare systems through a contact-page and email ([email protected]) motion, supplemented by LinkedIn presence and earned media (Forbes, PR Newswire). The company's capital history runs from non-dilutive SBIR grants from the National Science Foundation (2020, 2023) and the National Cancer Institute (2021), totaling approximately $1.645 million, to its first equity investment from RPV Fund in 2024. In October 2025, MALCOVA entered a three-way co-development partnership with Triple Ring and Leo Cancer Care to extend its imaging platform into upright radiation therapy for breast cancer. The company is founder-led by co-founders Dr. Peymon Ghazi (CEO, imaging physicist) and Dr. Tara Ghazi (CBO, cognitive neuroscientist), supported by a Head of Hardware and Head of Software, with total headcount of 1-10 employees.
MALCOVA firmographics
Firmographics- Name
- MALCOVA
- Legal name
- Malcova, Inc.
- Website
- https://malcova.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MALCOVA is a pre-revenue medical device startup developing a patented Narrow-Beam CT scanner, proprietary Digital and Physical Twin models, and an AI-based Diagnostic Agent for early breast cancer detection in dense breast tissue and stroke imaging. It is Newark, California-based and founder-led as of 2025.
- Ownership category
- akta.pro rank
MALCOVA industry classification
Industry- Product category
- Medical Imaging Devices
- NAICS
- Irradiation Apparatus Manufacturing (334517), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Mammography & Breast Imaging Systems (HLAHABAF)
- akta.pro secondary industries
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Computed Tomography (CT) Systems (HLAHABAB), Breast Imaging Centers (Mammography/Tomosynthesis) (HLAFAKAD)
Keywords
Where MALCOVA is headquartered
LocationHeadquarters
- HQ city
- Newark
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MALCOVA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Medical Imaging Technology Licensing/Sale: Malcova generates revenue through the development and eventual commercialization of its proprietary medical imaging technology, including Narrow-Beam CT systems, digital and physical twins, and AI diagnostic software. As a pre-commercial or early-stage company, it has historically relied on non-dilutive SBIR funding and equity investment. Revenue streams are not yet publicly disclosed.
- SBIR Non-Dilutive Funding: The company previously relied on Small Business Innovation Research (SBIR) non-dilutive funding from NIH and NSF between 2021 and 2024 to advance its technology development. SBIR authorization lapsed on September 30, 2025.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
MALCOVA product offering
Product offeringCore offering
MALCOVA develops and sells a proprietary medical imaging platform built around its patented Narrow-Beam CT hardware, which delivers scatter-free, gantry-free 3D breast imaging at significantly lower radiation doses than traditional CT. The platform is complemented by Digital Twins and Physical Twins for AI model training, and an AI-based Diagnostic Agent that assists radiologists with early disease detection. The company targets hospitals, imaging centers, and healthcare systems for breast cancer and stroke detection.
Product overview
MALCOVA offers a unified medical imaging platform centered on three core innovations: patented Narrow-Beam CT technology for scatter-free 3D breast imaging, Digital Twins for virtual anatomical simulation, and Physical Twins for realistic phantom models. An AI-based Diagnostic Agent integrates with these imaging systems to assist radiologists. The platform is designed for early breast cancer and stroke detection, particularly for women with dense breast tissue, emphasizing patient comfort, reduced radiation exposure, and superior diagnostic accuracy.
Differentiator
Problem solved
Functional benefit
Products and services
- Narrow-Beam CT A patented scatter-free cone-beam CT imaging system for breast and radiology applications, providing contamination-free, detailed 3D imaging at significantly lower radiation doses than traditional CT. It is gantry-free, mobile, and adaptive to variations in tissue type and breast diameter. Designed for radiologists, hospitals, and imaging centers performing early breast cancer and stroke detection.
- Digital Twins High-fidelity, computer-based models that simulate real breast tissue morphology and behavior, offering limitless, bias-controllable training data for AI development without patient risk. Aimed at AI developers, researchers, and healthcare providers building diagnostic algorithms.
- Physical Twins Realistic, scan-ready phantoms derived from actual patient images, enabling repeatable imaging and AI training without radiation risk to patients. Designed for research institutions, AI developers, and clinical teams needing consistent, patient-derived test subjects.
- AI-based Diagnostic Agent An intelligent software assistant that relieves radiologist burden and reveals novel diagnostic insights to support early disease detection. Processes breast and radiology imaging to detect diseases at earliest stages with superior accuracy. Designed for radiologists, oncologists, and imaging centers.
Quantifiable outcome
- Significantly lower radiation dose compared to traditional CT imaging
- +2 more outcomes
Companies that use MALCOVA
Customer profileSegments2 records
Ideal customer profiles1 record
MALCOVA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature6 records
MALCOVA partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Triple RingcoreTriple Ring partnered with Malcova and Leo Cancer Care during Breast Cancer Awareness Month 2025 to develop patient-focused breast imaging and upright radiation therapy systems. The collaboration aims to improve early detection accuracy and treatment precision while reducing patient discomfort and anxiety.
- Leo Cancer CareminorLeo Cancer Care joined Malcova and Triple Ring in a三方 partnership to develop patient-focused breast imaging and upright radiation therapy systems. The collaboration focuses on improving early detection accuracy and treatment precision.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
MALCOVA competitors and assessment
Company assessmentDirect peers
- Hologic: Hologic is the dominant player in breast imaging hardware (Selenia Dimensions mammography, 3D tomosynthesis, I-View software), directly competing with Malcova's intended breast cancer detection use case for the same healthcare providers and radiologists.
- Koning Health: Koning Health produces a competing cone-beam breast CT (KBCT) system and is the closest direct competitor to Malcova's Narrow-Beam CT, targeting the same dense-breast imaging market with a similar non-compression, 3D imaging approach.
Broad incumbents
- GE HealthCare: GE HealthCare is a broad incumbent across CT, mammography, and AI imaging analytics (e.g., Senographe Pristina, Edison platform). It overlaps with Malcova in CT and breast imaging as part of a much larger portfolio of medical imaging systems.
- Siemens Healthineers: Siemens Healthineers manufactures CT systems (SOMATOM family) and women's health imaging, representing a broad incumbent competitor with deep R&D resources, established hospital relationships, and regulatory infrastructure Malcova must compete against.
- Philips Healthcare: Philips offers broad medical imaging portfolios including CT, mammography, and AI-enabled diagnostic tools. It is a broad incumbent competitor across the radiology market where Malcova intends to commercialize.
- Fujifilm Healthcare: Fujifilm Healthcare manufactures mammography systems, CT scanners, and women's imaging solutions, making it a broad incumbent competitor across the medical imaging categories where Malcova intends to compete.
- Carl Zeiss Meditec: Carl Zeiss Meditec provides optical and digital imaging systems for ophthalmology, surgery, and diagnostics. It represents an adjacent incumbent with deep optical engineering expertise comparable to Malcova's patented imaging approach, though in different clinical verticals.
Emerging players
- iCAD: iCAD provides AI-powered breast cancer detection and breast density assessment software (ProFound AI), directly comparable to Malcova's AI-based Diagnostic Agent and Digital Twins capabilities in serving radiologists' workflow needs.
- Volpara Health: Volpara Health offers breast imaging analytics software focused on density assessment, risk evaluation, and mammography reporting—targeting the same dense-breast patient population and radiologist workflow as Malcova's software offerings.
- ScreenPoint Medical: ScreenPoint Medical develops AI software (Transpara) for breast imaging analysis and decision support, competing with Malcova's AI Diagnostic Agent in delivering radiologist-assistive AI capabilities for earlier cancer detection.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
MALCOVA social profiles
Digital presenceMALCOVA financial estimates
Financial estimateRevenue estimate
Valuation estimate
MALCOVA leadership team
Management profileNumber of profiles
Profiles4 records
MALCOVA funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MALCOVA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MALCOVA
What does MALCOVA do?
MALCOVA develops and sells a proprietary medical imaging platform built around its patented Narrow-Beam CT hardware, which delivers scatter-free, gantry-free 3D breast imaging at significantly lower radiation doses than traditional CT. The platform is complemented by Digital Twins and Physical Twins for AI model training, and an AI-based Diagnostic Agent that assists radiologists with early disease detection. The company targets hospitals, imaging centers, and healthcare systems for breast cancer and stroke detection.
Is MALCOVA a public or private company?
MALCOVA is a private company. It is classified as venture growth investor backed and is currently operating.
When was MALCOVA founded?
MALCOVA was founded in 2021. It employs 1 to 10 people.
Where is MALCOVA based?
MALCOVA is headquartered in Newark, United States, in the North America region.
How does MALCOVA make money?
Two revenue lines are on record. Medical Imaging Technology Licensing/Sale is the primary driver. The others are SBIR Non-Dilutive Funding.
Who are MALCOVA's main competitors?
Direct peers on record are Hologic and Koning Health. Broad incumbents are GE HealthCare, Siemens Healthineers, Philips Healthcare, Fujifilm Healthcare and Carl Zeiss Meditec. Emerging players are iCAD, Volpara Health and ScreenPoint Medical.
Does MALCOVA have an API?
No public API is recorded for MALCOVA.
What industry is MALCOVA in?
MALCOVA's product category is Medical Imaging Devices. Its primary akta.pro industry code is HLAHABAF, Mammography & Breast Imaging Systems, with a secondary code of HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage). Its NAICS code is 334517 and its SIC code is 3844.